SCHEMBL2116757

SCHEMBL2116757

COc1cc(S(=O)(=O)Nc2cc(-c3ccns3)ccc2C)ccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
ALDH1A1 P00352 8/20 0.40
HPGD P15428 3/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 5/20 0.40
HSP90AA1 P07900 1/20 0.39
CYP2C9 P11712 3/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117734 0.86 KIT (0.44) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL2119304 0.86 ALDH1A1 (0.43) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL2119338 0.84 GHSR (0.47) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL2118049 0.82 ALDH1A1 (0.40) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL2119240 0.81 GHSR (0.42) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL2117745 0.81 ALDH1A1 (0.39) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL2121465 0.79 SCN9A (0.46) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL2119300 0.79 ACLY (0.54) MAPTPTGES2
SCHEMBL2119290 0.79 TRIM24 (0.55) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL2117520 0.78 MAPT (0.39) MAPTALDH1A1HPGDSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 MAPT 4747/4885ALDH1A1 1063/4885HPGD 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.